The web broadcast of the conference call will be available for replay through Monday, April 3, 2017. To access the conference call, follow these instructions: Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international) Passcode : 75461730 (Nektar Therapeutics is the host) About Nektar Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, that is in Phase 1/2 clinical development for patients with solid tumors.